Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RT-102 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| RT-102 (80 μg) | COMBINATION_PRODUCT | RaniPill capsule containing PTH with doses of 20 and 80 μg |
| Forteo | DRUG | A commercial formulation of PTH for SC control (20 µg) |
| RT-102 (20 μg) | COMBINATION_PRODUCT | RaniPill capsule containing PTH with dose of 20μg |
RT-102 is an investigational small molecule being developed by Rani Therapeutics Holdings, Inc. (RANI). It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers, and one Phase 1 trial has been completed.
RT-102 is being studied for use in healthy volunteers. It is an investigational small molecule in Phase 1 clinical development. The completed trial evaluated the pharmacokinetics of parathyroid hormone (PTH) administered orally via the RaniPill capsule.
RT-102 is being developed by Rani Therapeutics Holdings, Inc., which trades under the ticker symbol RANI on the stock exchange. The company is conducting clinical trials to evaluate the drug in healthy volunteers.
RT-102 is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are no active trials currently ongoing. The drug is investigational and has not been approved by regulatory authorities.
RT-102 has one completed Phase 1 trial with the identifier NCT05164614. The trial, titled 'Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule,' enrolled 50 healthy volunteers and evaluated the pharmacokinetics of the drug.
RT-102 is not the same as PTH (parathyroid hormone). RT-102 is the investigational drug being studied, and PTH is the hormone that is administered in the trial. The study evaluates the pharmacokinetics of PTH when delivered orally via the RaniPill capsule.